nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—CYP1A2—Imiquimod—skin cancer	0.0659	0.124	CbGbCtD
Carvedilol—CYP1A1—Dacarbazine—skin cancer	0.0619	0.117	CbGbCtD
Carvedilol—CYP2E1—Dacarbazine—skin cancer	0.0478	0.09	CbGbCtD
Carvedilol—CYP2C9—Vismodegib—skin cancer	0.0411	0.0774	CbGbCtD
Carvedilol—ABCB1—Vismodegib—skin cancer	0.0399	0.0752	CbGbCtD
Carvedilol—CYP1A2—Vemurafenib—skin cancer	0.0361	0.0679	CbGbCtD
Carvedilol—CYP3A4—Imiquimod—skin cancer	0.0345	0.065	CbGbCtD
Carvedilol—CYP3A4—Temozolomide—skin cancer	0.0345	0.065	CbGbCtD
Carvedilol—CYP2D6—Vemurafenib—skin cancer	0.0297	0.056	CbGbCtD
Carvedilol—CYP1A2—Dacarbazine—skin cancer	0.0277	0.0521	CbGbCtD
Carvedilol—CYP3A4—Vismodegib—skin cancer	0.0239	0.045	CbGbCtD
Carvedilol—ABCB1—Dactinomycin—skin cancer	0.021	0.0395	CbGbCtD
Carvedilol—CYP3A4—Vemurafenib—skin cancer	0.0189	0.0356	CbGbCtD
Carvedilol—CYP1A2—Fluorouracil—skin cancer	0.0162	0.0305	CbGbCtD
Carvedilol—CYP2C9—Fluorouracil—skin cancer	0.0146	0.0275	CbGbCtD
Carvedilol—ABCB1—Docetaxel—skin cancer	0.0108	0.0204	CbGbCtD
Carvedilol—CYP3A4—Docetaxel—skin cancer	0.00649	0.0122	CbGbCtD
Carvedilol—NPPB—blood vessel—skin cancer	0.00568	0.0373	CbGeAlD
Carvedilol—GJA1—skin epidermis—skin cancer	0.00492	0.0323	CbGeAlD
Carvedilol—HIF1A—nerve—skin cancer	0.00432	0.0284	CbGeAlD
Carvedilol—SELE—endothelium—skin cancer	0.00416	0.0273	CbGeAlD
Carvedilol—SELE—blood vessel—skin cancer	0.00384	0.0252	CbGeAlD
Carvedilol—VCAM1—endothelium—skin cancer	0.00383	0.0251	CbGeAlD
Carvedilol—HIF1A—endothelium—skin cancer	0.00368	0.0242	CbGeAlD
Carvedilol—HIF1A—hair follicle—skin cancer	0.00362	0.0237	CbGeAlD
Carvedilol—GJA1—endothelium—skin cancer	0.00357	0.0234	CbGeAlD
Carvedilol—VCAM1—blood vessel—skin cancer	0.00353	0.0232	CbGeAlD
Carvedilol—GJA1—hair follicle—skin cancer	0.00351	0.023	CbGeAlD
Carvedilol—HIF1A—blood vessel—skin cancer	0.00339	0.0223	CbGeAlD
Carvedilol—GJA1—blood vessel—skin cancer	0.00329	0.0216	CbGeAlD
Carvedilol—SELE—nipple—skin cancer	0.00277	0.0182	CbGeAlD
Carvedilol—VCAM1—nipple—skin cancer	0.00255	0.0167	CbGeAlD
Carvedilol—VCAM1—neck—skin cancer	0.00252	0.0166	CbGeAlD
Carvedilol—HIF1A—nipple—skin cancer	0.00245	0.0161	CbGeAlD
Carvedilol—HIF1A—neck—skin cancer	0.00243	0.0159	CbGeAlD
Carvedilol—GJA1—nipple—skin cancer	0.00238	0.0156	CbGeAlD
Carvedilol—GJA1—neck—skin cancer	0.00236	0.0155	CbGeAlD
Carvedilol—NPPB—lymphoid tissue—skin cancer	0.00213	0.014	CbGeAlD
Carvedilol—NDUFC2—nipple—skin cancer	0.00207	0.0136	CbGeAlD
Carvedilol—NDUFC2—neck—skin cancer	0.00205	0.0135	CbGeAlD
Carvedilol—SELE—connective tissue—skin cancer	0.00197	0.0129	CbGeAlD
Carvedilol—SELE—epithelium—skin cancer	0.00187	0.0123	CbGeAlD
Carvedilol—VCAM1—connective tissue—skin cancer	0.00181	0.0119	CbGeAlD
Carvedilol—SELE—skin of body—skin cancer	0.00178	0.0117	CbGeAlD
Carvedilol—HIF1A—connective tissue—skin cancer	0.00174	0.0114	CbGeAlD
Carvedilol—VCAM1—epithelium—skin cancer	0.00172	0.0113	CbGeAlD
Carvedilol—NPPB—head—skin cancer	0.00172	0.0113	CbGeAlD
Carvedilol—GJA1—connective tissue—skin cancer	0.00169	0.0111	CbGeAlD
Carvedilol—HIF1A—epithelium—skin cancer	0.00165	0.0108	CbGeAlD
Carvedilol—SELE—mammalian vulva—skin cancer	0.00162	0.0106	CbGeAlD
Carvedilol—GJA1—epithelium—skin cancer	0.0016	0.0105	CbGeAlD
Carvedilol—HIF1A—skin of body—skin cancer	0.00157	0.0103	CbGeAlD
Carvedilol—ADRB3—connective tissue—skin cancer	0.00155	0.0102	CbGeAlD
Carvedilol—GJA1—skin of body—skin cancer	0.00152	0.01	CbGeAlD
Carvedilol—VCAM1—mammalian vulva—skin cancer	0.00149	0.00978	CbGeAlD
Carvedilol—SELE—lymphoid tissue—skin cancer	0.00144	0.00944	CbGeAlD
Carvedilol—HIF1A—mammalian vulva—skin cancer	0.00143	0.0094	CbGeAlD
Carvedilol—NDUFC2—epithelium—skin cancer	0.0014	0.00915	CbGeAlD
Carvedilol—GJA1—mammalian vulva—skin cancer	0.00139	0.00912	CbGeAlD
Carvedilol—SELE—female reproductive system—skin cancer	0.00139	0.0091	CbGeAlD
Carvedilol—VCAM1—lymphoid tissue—skin cancer	0.00132	0.00868	CbGeAlD
Carvedilol—VCAM1—female reproductive system—skin cancer	0.00128	0.00837	CbGeAlD
Carvedilol—HIF1A—lymphoid tissue—skin cancer	0.00127	0.00835	CbGeAlD
Carvedilol—GJA1—lymphoid tissue—skin cancer	0.00123	0.0081	CbGeAlD
Carvedilol—HIF1A—female reproductive system—skin cancer	0.00123	0.00805	CbGeAlD
Carvedilol—NDUFC2—mammalian vulva—skin cancer	0.00121	0.00794	CbGeAlD
Carvedilol—GJA1—female reproductive system—skin cancer	0.00119	0.00781	CbGeAlD
Carvedilol—CYP1A1—skin epidermis—skin cancer	0.00119	0.0078	CbGeAlD
Carvedilol—SELE—head—skin cancer	0.00116	0.0076	CbGeAlD
Carvedilol—VEGFA—mammalian vulva—skin cancer	0.0011	0.0072	CbGeAlD
Carvedilol—ADRB3—female reproductive system—skin cancer	0.00109	0.00716	CbGeAlD
Carvedilol—NDUFC2—lymphoid tissue—skin cancer	0.00107	0.00705	CbGeAlD
Carvedilol—VCAM1—head—skin cancer	0.00107	0.00699	CbGeAlD
Carvedilol—NDUFC2—female reproductive system—skin cancer	0.00104	0.0068	CbGeAlD
Carvedilol—HIF1A—head—skin cancer	0.00103	0.00673	CbGeAlD
Carvedilol—GJA1—head—skin cancer	0.000995	0.00653	CbGeAlD
Carvedilol—XDH—mammalian vulva—skin cancer	0.000977	0.00641	CbGeAlD
Carvedilol—NDUFC2—head—skin cancer	0.000866	0.00568	CbGeAlD
Carvedilol—XDH—female reproductive system—skin cancer	0.000837	0.00549	CbGeAlD
Carvedilol—ADRA1D—epithelium—skin cancer	0.000827	0.00543	CbGeAlD
Carvedilol—SELE—lymph node—skin cancer	0.000811	0.00532	CbGeAlD
Carvedilol—PTGS1—endothelium—skin cancer	0.000758	0.00497	CbGeAlD
Carvedilol—VCAM1—lymph node—skin cancer	0.000746	0.0049	CbGeAlD
Carvedilol—HIF1A—lymph node—skin cancer	0.000718	0.00471	CbGeAlD
Carvedilol—PTGS1—blood vessel—skin cancer	0.000699	0.00459	CbGeAlD
Carvedilol—GJA1—lymph node—skin cancer	0.000696	0.00457	CbGeAlD
Carvedilol—KCNH2—nipple—skin cancer	0.000681	0.00447	CbGeAlD
Carvedilol—ADRA2C—nipple—skin cancer	0.000672	0.00441	CbGeAlD
Carvedilol—ADRB1—connective tissue—skin cancer	0.000633	0.00415	CbGeAlD
Carvedilol—ADRA1D—female reproductive system—skin cancer	0.000614	0.00403	CbGeAlD
Carvedilol—NDUFC2—lymph node—skin cancer	0.000606	0.00398	CbGeAlD
Carvedilol—CYP1A2—nipple—skin cancer	0.000583	0.00383	CbGeAlD
Carvedilol—CYP1A1—nipple—skin cancer	0.000575	0.00377	CbGeAlD
Carvedilol—VEGFA—lymph node—skin cancer	0.00055	0.00361	CbGeAlD
Carvedilol—ADRA2A—nipple—skin cancer	0.000536	0.00352	CbGeAlD
Carvedilol—ADRA1B—head—skin cancer	0.000525	0.00344	CbGeAlD
Carvedilol—ADRA1D—head—skin cancer	0.000513	0.00337	CbGeAlD
Carvedilol—PTGS1—nipple—skin cancer	0.000505	0.00332	CbGeAlD
Carvedilol—ADRA1A—epithelium—skin cancer	0.000475	0.00312	CbGeAlD
Carvedilol—ADRB1—female reproductive system—skin cancer	0.000446	0.00293	CbGeAlD
Carvedilol—ABCB1—blood vessel—skin cancer	0.000413	0.00271	CbGeAlD
Carvedilol—ADRA2C—mammalian vulva—skin cancer	0.000393	0.00258	CbGeAlD
Carvedilol—CYP1A1—epithelium—skin cancer	0.000387	0.00254	CbGeAlD
Carvedilol—ADRA2A—connective tissue—skin cancer	0.00038	0.0025	CbGeAlD
Carvedilol—ADRB1—head—skin cancer	0.000373	0.00245	CbGeAlD
Carvedilol—CYP1A1—skin of body—skin cancer	0.000368	0.00242	CbGeAlD
Carvedilol—ADRA1A—lymphoid tissue—skin cancer	0.000366	0.0024	CbGeAlD
Carvedilol—PTGS1—connective tissue—skin cancer	0.000358	0.00235	CbGeAlD
Carvedilol—KCNH2—female reproductive system—skin cancer	0.000341	0.00224	CbGeAlD
Carvedilol—PTGS1—epithelium—skin cancer	0.00034	0.00223	CbGeAlD
Carvedilol—CYP1A1—mammalian vulva—skin cancer	0.000336	0.0022	CbGeAlD
Carvedilol—PTGS1—skin of body—skin cancer	0.000324	0.00212	CbGeAlD
Carvedilol—ADRA2A—mammalian vulva—skin cancer	0.000313	0.00206	CbGeAlD
Carvedilol—PTGS1—mammalian vulva—skin cancer	0.000295	0.00194	CbGeAlD
Carvedilol—ADRA1A—head—skin cancer	0.000295	0.00193	CbGeAlD
Carvedilol—CYP1A1—female reproductive system—skin cancer	0.000288	0.00189	CbGeAlD
Carvedilol—Body temperature increased—Imiquimod—skin cancer	0.000286	0.00134	CcSEcCtD
Carvedilol—Tinnitus—Temozolomide—skin cancer	0.000285	0.00134	CcSEcCtD
Carvedilol—KCNH2—head—skin cancer	0.000285	0.00187	CbGeAlD
Carvedilol—Malaise—Bleomycin—skin cancer	0.000284	0.00133	CcSEcCtD
Carvedilol—Haemoglobin—Fluorouracil—skin cancer	0.000283	0.00133	CcSEcCtD
Carvedilol—Leukopenia—Bleomycin—skin cancer	0.000282	0.00132	CcSEcCtD
Carvedilol—Rhinitis—Fluorouracil—skin cancer	0.000282	0.00132	CcSEcCtD
Carvedilol—Haemorrhage—Fluorouracil—skin cancer	0.000281	0.00132	CcSEcCtD
Carvedilol—Dizziness—Vemurafenib—skin cancer	0.000281	0.00132	CcSEcCtD
Carvedilol—ADRA2C—head—skin cancer	0.000281	0.00184	CbGeAlD
Carvedilol—Hypoaesthesia—Fluorouracil—skin cancer	0.00028	0.00131	CcSEcCtD
Carvedilol—Pharyngitis—Fluorouracil—skin cancer	0.000279	0.00131	CcSEcCtD
Carvedilol—Angiopathy—Temozolomide—skin cancer	0.000277	0.0013	CcSEcCtD
Carvedilol—CYP2C9—female reproductive system—skin cancer	0.000277	0.00182	CbGeAlD
Carvedilol—Immune system disorder—Temozolomide—skin cancer	0.000276	0.00129	CcSEcCtD
Carvedilol—Mediastinal disorder—Temozolomide—skin cancer	0.000275	0.00129	CcSEcCtD
Carvedilol—Cough—Bleomycin—skin cancer	0.000275	0.00129	CcSEcCtD
Carvedilol—Dehydration—Docetaxel—skin cancer	0.000273	0.00128	CcSEcCtD
Carvedilol—Ill-defined disorder—Dactinomycin—skin cancer	0.000273	0.00128	CcSEcCtD
Carvedilol—CYP2E1—lymphoid tissue—skin cancer	0.000272	0.00179	CbGeAlD
Carvedilol—Anaemia—Dactinomycin—skin cancer	0.000272	0.00127	CcSEcCtD
Carvedilol—Vomiting—Vemurafenib—skin cancer	0.00027	0.00127	CcSEcCtD
Carvedilol—Alopecia—Temozolomide—skin cancer	0.00027	0.00127	CcSEcCtD
Carvedilol—Myalgia—Bleomycin—skin cancer	0.000268	0.00126	CcSEcCtD
Carvedilol—Chest pain—Bleomycin—skin cancer	0.000268	0.00126	CcSEcCtD
Carvedilol—Orthostatic hypotension—Docetaxel—skin cancer	0.000268	0.00126	CcSEcCtD
Carvedilol—ADRA2A—female reproductive system—skin cancer	0.000268	0.00176	CbGeAlD
Carvedilol—Rash—Vemurafenib—skin cancer	0.000268	0.00126	CcSEcCtD
Carvedilol—Dermatitis—Vemurafenib—skin cancer	0.000268	0.00125	CcSEcCtD
Carvedilol—Hypersensitivity—Imiquimod—skin cancer	0.000267	0.00125	CcSEcCtD
Carvedilol—Headache—Vemurafenib—skin cancer	0.000266	0.00125	CcSEcCtD
Carvedilol—Malnutrition—Temozolomide—skin cancer	0.000266	0.00125	CcSEcCtD
Carvedilol—Discomfort—Bleomycin—skin cancer	0.000265	0.00124	CcSEcCtD
Carvedilol—Malaise—Dactinomycin—skin cancer	0.000265	0.00124	CcSEcCtD
Carvedilol—Cramp muscle—Docetaxel—skin cancer	0.000264	0.00124	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000264	0.00124	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000264	0.00124	CcSEcCtD
Carvedilol—Leukopenia—Dactinomycin—skin cancer	0.000263	0.00123	CcSEcCtD
Carvedilol—Nasopharyngitis—Docetaxel—skin cancer	0.000263	0.00123	CcSEcCtD
Carvedilol—CYP2E1—female reproductive system—skin cancer	0.000262	0.00172	CbGeAlD
Carvedilol—Asthenia—Imiquimod—skin cancer	0.00026	0.00122	CcSEcCtD
Carvedilol—Confusional state—Bleomycin—skin cancer	0.000259	0.00122	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000259	0.00121	CcSEcCtD
Carvedilol—Anaphylactic shock—Bleomycin—skin cancer	0.000257	0.00121	CcSEcCtD
Carvedilol—Oedema—Bleomycin—skin cancer	0.000257	0.00121	CcSEcCtD
Carvedilol—Back pain—Temozolomide—skin cancer	0.000257	0.00121	CcSEcCtD
Carvedilol—Pruritus—Imiquimod—skin cancer	0.000256	0.0012	CcSEcCtD
Carvedilol—Infection—Bleomycin—skin cancer	0.000256	0.0012	CcSEcCtD
Carvedilol—PTGS1—female reproductive system—skin cancer	0.000253	0.00166	CbGeAlD
Carvedilol—Nausea—Vemurafenib—skin cancer	0.000252	0.00118	CcSEcCtD
Carvedilol—Thrombocytopenia—Bleomycin—skin cancer	0.000252	0.00118	CcSEcCtD
Carvedilol—Vision blurred—Temozolomide—skin cancer	0.000251	0.00117	CcSEcCtD
Carvedilol—Myalgia—Dactinomycin—skin cancer	0.00025	0.00117	CcSEcCtD
Carvedilol—Bronchospasm—Docetaxel—skin cancer	0.00025	0.00117	CcSEcCtD
Carvedilol—Alopecia—Fluorouracil—skin cancer	0.000249	0.00117	CcSEcCtD
Carvedilol—Diarrhoea—Imiquimod—skin cancer	0.000248	0.00116	CcSEcCtD
Carvedilol—Discomfort—Dactinomycin—skin cancer	0.000247	0.00116	CcSEcCtD
Carvedilol—Angina pectoris—Docetaxel—skin cancer	0.000247	0.00116	CcSEcCtD
Carvedilol—Ill-defined disorder—Temozolomide—skin cancer	0.000247	0.00116	CcSEcCtD
Carvedilol—Anaemia—Temozolomide—skin cancer	0.000246	0.00115	CcSEcCtD
Carvedilol—Anorexia—Bleomycin—skin cancer	0.000245	0.00115	CcSEcCtD
Carvedilol—Angioedema—Temozolomide—skin cancer	0.000243	0.00114	CcSEcCtD
Carvedilol—Pancytopenia—Docetaxel—skin cancer	0.000241	0.00113	CcSEcCtD
Carvedilol—Hypotension—Bleomycin—skin cancer	0.00024	0.00113	CcSEcCtD
Carvedilol—CYP1A1—head—skin cancer	0.00024	0.00158	CbGeAlD
Carvedilol—Oedema—Dactinomycin—skin cancer	0.00024	0.00112	CcSEcCtD
Carvedilol—Malaise—Temozolomide—skin cancer	0.00024	0.00112	CcSEcCtD
Carvedilol—Dizziness—Imiquimod—skin cancer	0.00024	0.00112	CcSEcCtD
Carvedilol—Vertigo—Temozolomide—skin cancer	0.000239	0.00112	CcSEcCtD
Carvedilol—Infection—Dactinomycin—skin cancer	0.000238	0.00112	CcSEcCtD
Carvedilol—Leukopenia—Temozolomide—skin cancer	0.000238	0.00112	CcSEcCtD
Carvedilol—Palpitations—Temozolomide—skin cancer	0.000235	0.0011	CcSEcCtD
Carvedilol—Thrombocytopenia—Dactinomycin—skin cancer	0.000235	0.0011	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000234	0.0011	CcSEcCtD
Carvedilol—Cough—Temozolomide—skin cancer	0.000232	0.00109	CcSEcCtD
Carvedilol—Paraesthesia—Bleomycin—skin cancer	0.000231	0.00108	CcSEcCtD
Carvedilol—Weight increased—Docetaxel—skin cancer	0.000231	0.00108	CcSEcCtD
Carvedilol—Vision blurred—Fluorouracil—skin cancer	0.000231	0.00108	CcSEcCtD
Carvedilol—Convulsion—Temozolomide—skin cancer	0.00023	0.00108	CcSEcCtD
Carvedilol—Vomiting—Imiquimod—skin cancer	0.00023	0.00108	CcSEcCtD
Carvedilol—Weight decreased—Docetaxel—skin cancer	0.00023	0.00108	CcSEcCtD
Carvedilol—Hypertension—Temozolomide—skin cancer	0.00023	0.00108	CcSEcCtD
Carvedilol—Dyspnoea—Bleomycin—skin cancer	0.000229	0.00108	CcSEcCtD
Carvedilol—Anorexia—Dactinomycin—skin cancer	0.000229	0.00107	CcSEcCtD
Carvedilol—Rash—Imiquimod—skin cancer	0.000228	0.00107	CcSEcCtD
Carvedilol—Dermatitis—Imiquimod—skin cancer	0.000228	0.00107	CcSEcCtD
Carvedilol—Pneumonia—Docetaxel—skin cancer	0.000228	0.00107	CcSEcCtD
Carvedilol—Headache—Imiquimod—skin cancer	0.000227	0.00106	CcSEcCtD
Carvedilol—Anaemia—Fluorouracil—skin cancer	0.000226	0.00106	CcSEcCtD
Carvedilol—Myalgia—Temozolomide—skin cancer	0.000226	0.00106	CcSEcCtD
Carvedilol—Arthralgia—Temozolomide—skin cancer	0.000226	0.00106	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000225	0.00105	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000224	0.00105	CcSEcCtD
Carvedilol—ADRA2A—head—skin cancer	0.000224	0.00147	CbGeAlD
Carvedilol—Discomfort—Temozolomide—skin cancer	0.000224	0.00105	CcSEcCtD
Carvedilol—Decreased appetite—Bleomycin—skin cancer	0.000224	0.00105	CcSEcCtD
Carvedilol—Acute coronary syndrome—Docetaxel—skin cancer	0.000223	0.00105	CcSEcCtD
Carvedilol—Renal failure—Docetaxel—skin cancer	0.000222	0.00104	CcSEcCtD
Carvedilol—Myocardial infarction—Docetaxel—skin cancer	0.000222	0.00104	CcSEcCtD
Carvedilol—Dry mouth—Temozolomide—skin cancer	0.000221	0.00104	CcSEcCtD
Carvedilol—Pain—Bleomycin—skin cancer	0.00022	0.00103	CcSEcCtD
Carvedilol—Leukopenia—Fluorouracil—skin cancer	0.000219	0.00103	CcSEcCtD
Carvedilol—CYP2E1—head—skin cancer	0.000219	0.00144	CbGeAlD
Carvedilol—Confusional state—Temozolomide—skin cancer	0.000219	0.00103	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000219	0.00102	CcSEcCtD
Carvedilol—Anaphylactic shock—Temozolomide—skin cancer	0.000217	0.00102	CcSEcCtD
Carvedilol—Oedema—Temozolomide—skin cancer	0.000217	0.00102	CcSEcCtD
Carvedilol—Infection—Temozolomide—skin cancer	0.000216	0.00101	CcSEcCtD
Carvedilol—Nausea—Imiquimod—skin cancer	0.000215	0.00101	CcSEcCtD
Carvedilol—Thrombocytopenia—Temozolomide—skin cancer	0.000213	0.000996	CcSEcCtD
Carvedilol—Convulsion—Fluorouracil—skin cancer	0.000212	0.000995	CcSEcCtD
Carvedilol—Feeling abnormal—Bleomycin—skin cancer	0.000212	0.000994	CcSEcCtD
Carvedilol—PTGS1—head—skin cancer	0.000211	0.00139	CbGeAlD
Carvedilol—CYP3A4—female reproductive system—skin cancer	0.000211	0.00139	CbGeAlD
Carvedilol—Skin disorder—Temozolomide—skin cancer	0.000211	0.000988	CcSEcCtD
Carvedilol—Hyperhidrosis—Temozolomide—skin cancer	0.00021	0.000983	CcSEcCtD
Carvedilol—Chest pain—Fluorouracil—skin cancer	0.000209	0.000978	CcSEcCtD
Carvedilol—Myalgia—Fluorouracil—skin cancer	0.000209	0.000978	CcSEcCtD
Carvedilol—Decreased appetite—Dactinomycin—skin cancer	0.000209	0.000978	CcSEcCtD
Carvedilol—CYP2D6—female reproductive system—skin cancer	0.000208	0.00136	CbGeAlD
Carvedilol—Fatigue—Dactinomycin—skin cancer	0.000207	0.00097	CcSEcCtD
Carvedilol—Anorexia—Temozolomide—skin cancer	0.000207	0.00097	CcSEcCtD
Carvedilol—Discomfort—Fluorouracil—skin cancer	0.000206	0.000966	CcSEcCtD
Carvedilol—Pain—Dactinomycin—skin cancer	0.000205	0.000962	CcSEcCtD
Carvedilol—Urticaria—Bleomycin—skin cancer	0.000204	0.000958	CcSEcCtD
Carvedilol—Haemoglobin—Docetaxel—skin cancer	0.000204	0.000957	CcSEcCtD
Carvedilol—Rhinitis—Docetaxel—skin cancer	0.000204	0.000955	CcSEcCtD
Carvedilol—Body temperature increased—Bleomycin—skin cancer	0.000203	0.000953	CcSEcCtD
Carvedilol—Haemorrhage—Docetaxel—skin cancer	0.000203	0.000952	CcSEcCtD
Carvedilol—Hypoaesthesia—Docetaxel—skin cancer	0.000202	0.000947	CcSEcCtD
Carvedilol—Confusional state—Fluorouracil—skin cancer	0.000202	0.000945	CcSEcCtD
Carvedilol—Pharyngitis—Docetaxel—skin cancer	0.000202	0.000945	CcSEcCtD
Carvedilol—ABCB1—epithelium—skin cancer	0.000201	0.00132	CbGeAlD
Carvedilol—Urinary tract disorder—Docetaxel—skin cancer	0.000201	0.00094	CcSEcCtD
Carvedilol—Oedema peripheral—Docetaxel—skin cancer	0.0002	0.000938	CcSEcCtD
Carvedilol—Anaphylactic shock—Fluorouracil—skin cancer	0.0002	0.000937	CcSEcCtD
Carvedilol—Oedema—Fluorouracil—skin cancer	0.0002	0.000937	CcSEcCtD
Carvedilol—KCNH2—lymph node—skin cancer	0.000199	0.00131	CbGeAlD
Carvedilol—Urethral disorder—Docetaxel—skin cancer	0.000199	0.000933	CcSEcCtD
Carvedilol—Infection—Fluorouracil—skin cancer	0.000199	0.000931	CcSEcCtD
Carvedilol—Feeling abnormal—Dactinomycin—skin cancer	0.000198	0.000927	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000198	0.000927	CcSEcCtD
Carvedilol—ADRA2C—lymph node—skin cancer	0.000197	0.00129	CbGeAlD
Carvedilol—Insomnia—Temozolomide—skin cancer	0.000196	0.00092	CcSEcCtD
Carvedilol—Gastrointestinal pain—Dactinomycin—skin cancer	0.000196	0.00092	CcSEcCtD
Carvedilol—Thrombocytopenia—Fluorouracil—skin cancer	0.000196	0.000918	CcSEcCtD
Carvedilol—Visual impairment—Docetaxel—skin cancer	0.000196	0.000918	CcSEcCtD
Carvedilol—Tachycardia—Fluorouracil—skin cancer	0.000195	0.000915	CcSEcCtD
Carvedilol—Paraesthesia—Temozolomide—skin cancer	0.000195	0.000914	CcSEcCtD
Carvedilol—Dyspnoea—Temozolomide—skin cancer	0.000194	0.000907	CcSEcCtD
Carvedilol—Somnolence—Temozolomide—skin cancer	0.000193	0.000904	CcSEcCtD
Carvedilol—Erythema multiforme—Docetaxel—skin cancer	0.000192	0.0009	CcSEcCtD
Carvedilol—Dyspepsia—Temozolomide—skin cancer	0.000191	0.000896	CcSEcCtD
Carvedilol—Anorexia—Fluorouracil—skin cancer	0.000191	0.000893	CcSEcCtD
Carvedilol—Body temperature increased—Dactinomycin—skin cancer	0.00019	0.000889	CcSEcCtD
Carvedilol—Abdominal pain—Dactinomycin—skin cancer	0.00019	0.000889	CcSEcCtD
Carvedilol—Hypersensitivity—Bleomycin—skin cancer	0.00019	0.000889	CcSEcCtD
Carvedilol—Decreased appetite—Temozolomide—skin cancer	0.000189	0.000884	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Temozolomide—skin cancer	0.000187	0.000878	CcSEcCtD
Carvedilol—Fatigue—Temozolomide—skin cancer	0.000187	0.000877	CcSEcCtD
Carvedilol—Hypotension—Fluorouracil—skin cancer	0.000187	0.000876	CcSEcCtD
Carvedilol—Pain—Temozolomide—skin cancer	0.000186	0.00087	CcSEcCtD
Carvedilol—Constipation—Temozolomide—skin cancer	0.000186	0.00087	CcSEcCtD
Carvedilol—Asthenia—Bleomycin—skin cancer	0.000185	0.000865	CcSEcCtD
Carvedilol—Angiopathy—Docetaxel—skin cancer	0.000184	0.000864	CcSEcCtD
Carvedilol—Immune system disorder—Docetaxel—skin cancer	0.000184	0.00086	CcSEcCtD
Carvedilol—Mediastinal disorder—Docetaxel—skin cancer	0.000183	0.000858	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000182	0.000854	CcSEcCtD
Carvedilol—Pruritus—Bleomycin—skin cancer	0.000182	0.000853	CcSEcCtD
Carvedilol—Insomnia—Fluorouracil—skin cancer	0.000181	0.000848	CcSEcCtD
Carvedilol—Paraesthesia—Fluorouracil—skin cancer	0.00018	0.000842	CcSEcCtD
Carvedilol—Alopecia—Docetaxel—skin cancer	0.00018	0.000841	CcSEcCtD
Carvedilol—Feeling abnormal—Temozolomide—skin cancer	0.000179	0.000838	CcSEcCtD
Carvedilol—Dyspnoea—Fluorouracil—skin cancer	0.000178	0.000836	CcSEcCtD
Carvedilol—Somnolence—Fluorouracil—skin cancer	0.000178	0.000833	CcSEcCtD
Carvedilol—Gastrointestinal pain—Temozolomide—skin cancer	0.000177	0.000832	CcSEcCtD
Carvedilol—Malnutrition—Docetaxel—skin cancer	0.000177	0.000829	CcSEcCtD
Carvedilol—Hypersensitivity—Dactinomycin—skin cancer	0.000177	0.000829	CcSEcCtD
Carvedilol—Dyspepsia—Fluorouracil—skin cancer	0.000176	0.000825	CcSEcCtD
Carvedilol—ABCB1—mammalian vulva—skin cancer	0.000175	0.00115	CbGeAlD
Carvedilol—Decreased appetite—Fluorouracil—skin cancer	0.000174	0.000815	CcSEcCtD
Carvedilol—CYP2D6—head—skin cancer	0.000174	0.00114	CbGeAlD
Carvedilol—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000173	0.000809	CcSEcCtD
Carvedilol—Urticaria—Temozolomide—skin cancer	0.000172	0.000808	CcSEcCtD
Carvedilol—Asthenia—Dactinomycin—skin cancer	0.000172	0.000807	CcSEcCtD
Carvedilol—Body temperature increased—Temozolomide—skin cancer	0.000172	0.000804	CcSEcCtD
Carvedilol—Abdominal pain—Temozolomide—skin cancer	0.000172	0.000804	CcSEcCtD
Carvedilol—Back pain—Docetaxel—skin cancer	0.000171	0.000802	CcSEcCtD
Carvedilol—Pain—Fluorouracil—skin cancer	0.000171	0.000802	CcSEcCtD
Carvedilol—Muscle spasms—Docetaxel—skin cancer	0.00017	0.000797	CcSEcCtD
Carvedilol—CYP1A1—lymph node—skin cancer	0.000168	0.0011	CbGeAlD
Carvedilol—Feeling abnormal—Fluorouracil—skin cancer	0.000165	0.000772	CcSEcCtD
Carvedilol—Diarrhoea—Dactinomycin—skin cancer	0.000164	0.00077	CcSEcCtD
Carvedilol—Vomiting—Bleomycin—skin cancer	0.000164	0.000767	CcSEcCtD
Carvedilol—Anaemia—Docetaxel—skin cancer	0.000163	0.000766	CcSEcCtD
Carvedilol—Rash—Bleomycin—skin cancer	0.000162	0.00076	CcSEcCtD
Carvedilol—Dermatitis—Bleomycin—skin cancer	0.000162	0.00076	CcSEcCtD
Carvedilol—Hypersensitivity—Temozolomide—skin cancer	0.00016	0.00075	CcSEcCtD
Carvedilol—Urticaria—Fluorouracil—skin cancer	0.000159	0.000745	CcSEcCtD
Carvedilol—Syncope—Docetaxel—skin cancer	0.000159	0.000743	CcSEcCtD
Carvedilol—Leukopenia—Docetaxel—skin cancer	0.000158	0.000742	CcSEcCtD
Carvedilol—Body temperature increased—Fluorouracil—skin cancer	0.000158	0.000741	CcSEcCtD
Carvedilol—ADRA2A—lymph node—skin cancer	0.000157	0.00103	CbGeAlD
Carvedilol—Palpitations—Docetaxel—skin cancer	0.000156	0.000733	CcSEcCtD
Carvedilol—Asthenia—Temozolomide—skin cancer	0.000156	0.00073	CcSEcCtD
Carvedilol—Loss of consciousness—Docetaxel—skin cancer	0.000155	0.000729	CcSEcCtD
Carvedilol—ABCB1—lymphoid tissue—skin cancer	0.000155	0.00102	CbGeAlD
Carvedilol—Cough—Docetaxel—skin cancer	0.000154	0.000723	CcSEcCtD
Carvedilol—Pruritus—Temozolomide—skin cancer	0.000154	0.00072	CcSEcCtD
Carvedilol—Convulsion—Docetaxel—skin cancer	0.000153	0.000718	CcSEcCtD
Carvedilol—Nausea—Bleomycin—skin cancer	0.000153	0.000716	CcSEcCtD
Carvedilol—Hypertension—Docetaxel—skin cancer	0.000153	0.000716	CcSEcCtD
Carvedilol—Vomiting—Dactinomycin—skin cancer	0.000153	0.000715	CcSEcCtD
Carvedilol—Rash—Dactinomycin—skin cancer	0.000151	0.000709	CcSEcCtD
Carvedilol—Chest pain—Docetaxel—skin cancer	0.000151	0.000706	CcSEcCtD
Carvedilol—Myalgia—Docetaxel—skin cancer	0.000151	0.000706	CcSEcCtD
Carvedilol—Arthralgia—Docetaxel—skin cancer	0.000151	0.000706	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00015	0.000701	CcSEcCtD
Carvedilol—ABCB1—female reproductive system—skin cancer	0.000149	0.000981	CbGeAlD
Carvedilol—Diarrhoea—Temozolomide—skin cancer	0.000149	0.000696	CcSEcCtD
Carvedilol—PTGS1—lymph node—skin cancer	0.000148	0.00097	CbGeAlD
Carvedilol—Hypersensitivity—Fluorouracil—skin cancer	0.000147	0.000691	CcSEcCtD
Carvedilol—Dry mouth—Docetaxel—skin cancer	0.000147	0.00069	CcSEcCtD
Carvedilol—Confusional state—Docetaxel—skin cancer	0.000146	0.000682	CcSEcCtD
Carvedilol—Oedema—Docetaxel—skin cancer	0.000144	0.000677	CcSEcCtD
Carvedilol—Anaphylactic shock—Docetaxel—skin cancer	0.000144	0.000677	CcSEcCtD
Carvedilol—Dizziness—Temozolomide—skin cancer	0.000144	0.000673	CcSEcCtD
Carvedilol—Infection—Docetaxel—skin cancer	0.000143	0.000672	CcSEcCtD
Carvedilol—Nausea—Dactinomycin—skin cancer	0.000143	0.000668	CcSEcCtD
Carvedilol—Shock—Docetaxel—skin cancer	0.000142	0.000666	CcSEcCtD
Carvedilol—Pruritus—Fluorouracil—skin cancer	0.000141	0.000663	CcSEcCtD
Carvedilol—Thrombocytopenia—Docetaxel—skin cancer	0.000141	0.000662	CcSEcCtD
Carvedilol—Tachycardia—Docetaxel—skin cancer	0.000141	0.00066	CcSEcCtD
Carvedilol—Skin disorder—Docetaxel—skin cancer	0.00014	0.000657	CcSEcCtD
Carvedilol—Vomiting—Temozolomide—skin cancer	0.000138	0.000647	CcSEcCtD
Carvedilol—Anorexia—Docetaxel—skin cancer	0.000138	0.000645	CcSEcCtD
Carvedilol—Rash—Temozolomide—skin cancer	0.000137	0.000641	CcSEcCtD
Carvedilol—Diarrhoea—Fluorouracil—skin cancer	0.000137	0.000641	CcSEcCtD
Carvedilol—Dermatitis—Temozolomide—skin cancer	0.000137	0.000641	CcSEcCtD
Carvedilol—Headache—Temozolomide—skin cancer	0.000136	0.000637	CcSEcCtD
Carvedilol—Hypotension—Docetaxel—skin cancer	0.000135	0.000632	CcSEcCtD
Carvedilol—Dizziness—Fluorouracil—skin cancer	0.000132	0.00062	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000132	0.000616	CcSEcCtD
Carvedilol—Insomnia—Docetaxel—skin cancer	0.000131	0.000612	CcSEcCtD
Carvedilol—Paraesthesia—Docetaxel—skin cancer	0.00013	0.000608	CcSEcCtD
Carvedilol—Nausea—Temozolomide—skin cancer	0.000129	0.000604	CcSEcCtD
Carvedilol—Dyspnoea—Docetaxel—skin cancer	0.000129	0.000603	CcSEcCtD
Carvedilol—Somnolence—Docetaxel—skin cancer	0.000128	0.000601	CcSEcCtD
Carvedilol—Vomiting—Fluorouracil—skin cancer	0.000127	0.000596	CcSEcCtD
Carvedilol—Dyspepsia—Docetaxel—skin cancer	0.000127	0.000596	CcSEcCtD
Carvedilol—Rash—Fluorouracil—skin cancer	0.000126	0.000591	CcSEcCtD
Carvedilol—Dermatitis—Fluorouracil—skin cancer	0.000126	0.00059	CcSEcCtD
Carvedilol—Decreased appetite—Docetaxel—skin cancer	0.000125	0.000588	CcSEcCtD
Carvedilol—Headache—Fluorouracil—skin cancer	0.000125	0.000587	CcSEcCtD
Carvedilol—ABCB1—head—skin cancer	0.000125	0.000819	CbGeAlD
Carvedilol—Gastrointestinal disorder—Docetaxel—skin cancer	0.000125	0.000584	CcSEcCtD
Carvedilol—Fatigue—Docetaxel—skin cancer	0.000124	0.000583	CcSEcCtD
Carvedilol—Pain—Docetaxel—skin cancer	0.000123	0.000579	CcSEcCtD
Carvedilol—Constipation—Docetaxel—skin cancer	0.000123	0.000579	CcSEcCtD
Carvedilol—Feeling abnormal—Docetaxel—skin cancer	0.000119	0.000558	CcSEcCtD
Carvedilol—Nausea—Fluorouracil—skin cancer	0.000119	0.000557	CcSEcCtD
Carvedilol—Gastrointestinal pain—Docetaxel—skin cancer	0.000118	0.000553	CcSEcCtD
Carvedilol—Body temperature increased—Docetaxel—skin cancer	0.000114	0.000535	CcSEcCtD
Carvedilol—Abdominal pain—Docetaxel—skin cancer	0.000114	0.000535	CcSEcCtD
Carvedilol—Hypersensitivity—Docetaxel—skin cancer	0.000106	0.000498	CcSEcCtD
Carvedilol—Asthenia—Docetaxel—skin cancer	0.000104	0.000485	CcSEcCtD
Carvedilol—Pruritus—Docetaxel—skin cancer	0.000102	0.000479	CcSEcCtD
Carvedilol—Diarrhoea—Docetaxel—skin cancer	9.88e-05	0.000463	CcSEcCtD
Carvedilol—Dizziness—Docetaxel—skin cancer	9.55e-05	0.000447	CcSEcCtD
Carvedilol—Vomiting—Docetaxel—skin cancer	9.18e-05	0.00043	CcSEcCtD
Carvedilol—Rash—Docetaxel—skin cancer	9.1e-05	0.000427	CcSEcCtD
Carvedilol—Dermatitis—Docetaxel—skin cancer	9.09e-05	0.000426	CcSEcCtD
Carvedilol—Headache—Docetaxel—skin cancer	9.04e-05	0.000424	CcSEcCtD
Carvedilol—ABCB1—lymph node—skin cancer	8.74e-05	0.000574	CbGeAlD
Carvedilol—Nausea—Docetaxel—skin cancer	8.57e-05	0.000402	CcSEcCtD
Carvedilol—ADRA1B—Signaling Pathways—GLI1—skin cancer	2.9e-05	0.000281	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	2.86e-05	0.000277	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.8e-05	0.000272	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CSPG4—skin cancer	2.8e-05	0.000271	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SUFU—skin cancer	2.79e-05	0.000271	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PTCH1—skin cancer	2.78e-05	0.000269	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—SMO—skin cancer	2.78e-05	0.000269	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SUFU—skin cancer	2.75e-05	0.000267	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—GLI2—skin cancer	2.74e-05	0.000266	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—KRAS—skin cancer	2.71e-05	0.000263	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PTGER4—skin cancer	2.7e-05	0.000262	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.68e-05	0.00026	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—KRAS—skin cancer	2.66e-05	0.000258	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CSPG4—skin cancer	2.64e-05	0.000256	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MC1R—skin cancer	2.61e-05	0.000253	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PLIN2—skin cancer	2.61e-05	0.000253	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—GLI1—skin cancer	2.58e-05	0.00025	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ENO2—skin cancer	2.55e-05	0.000247	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—GLI2—skin cancer	2.55e-05	0.000247	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ENO2—skin cancer	2.54e-05	0.000247	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	2.54e-05	0.000246	CbGpPWpGaD
Carvedilol—HIF1A—Disease—HRAS—skin cancer	2.54e-05	0.000246	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SHH—skin cancer	2.53e-05	0.000245	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—RASA1—skin cancer	2.51e-05	0.000243	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PLIN2—skin cancer	2.46e-05	0.000239	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SUFU—skin cancer	2.44e-05	0.000237	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PLIN2—skin cancer	2.44e-05	0.000237	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.43e-05	0.000236	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—NRAS—skin cancer	2.43e-05	0.000236	CbGpPWpGaD
Carvedilol—HIF1A—Disease—IL6—skin cancer	2.43e-05	0.000236	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MC1R—skin cancer	2.43e-05	0.000235	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SMO—skin cancer	2.39e-05	0.000232	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTCH1—skin cancer	2.39e-05	0.000232	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—GLI1—skin cancer	2.39e-05	0.000232	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TP53—skin cancer	2.37e-05	0.000229	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTGER4—skin cancer	2.33e-05	0.000226	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.33e-05	0.000226	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—HRAS—skin cancer	2.31e-05	0.000224	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SHH—skin cancer	2.3e-05	0.000223	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RASA1—skin cancer	2.29e-05	0.000222	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SHH—skin cancer	2.28e-05	0.000221	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SUFU—skin cancer	2.27e-05	0.00022	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RASA1—skin cancer	2.27e-05	0.00022	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—HRAS—skin cancer	2.26e-05	0.000219	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SHH—skin cancer	2.25e-05	0.000218	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RASA1—skin cancer	2.24e-05	0.000217	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—IL6—skin cancer	2.21e-05	0.000214	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SMO—skin cancer	2.18e-05	0.000212	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTCH1—skin cancer	2.18e-05	0.000212	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SMO—skin cancer	2.16e-05	0.00021	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTCH1—skin cancer	2.16e-05	0.00021	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.16e-05	0.000209	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SMO—skin cancer	2.13e-05	0.000207	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTCH1—skin cancer	2.13e-05	0.000207	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SHH—skin cancer	2.13e-05	0.000207	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTGER4—skin cancer	2.12e-05	0.000206	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RASA1—skin cancer	2.12e-05	0.000205	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TERT—skin cancer	2.11e-05	0.000205	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TERT—skin cancer	2.11e-05	0.000204	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CSPG4—skin cancer	2.11e-05	0.000204	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTGER4—skin cancer	2.1e-05	0.000204	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SHH—skin cancer	2.1e-05	0.000203	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—KRAS—skin cancer	2.09e-05	0.000203	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PLIN2—skin cancer	2.09e-05	0.000202	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RASA1—skin cancer	2.08e-05	0.000202	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTGER4—skin cancer	2.08e-05	0.000201	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ENO2—skin cancer	2.07e-05	0.000201	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.07e-05	0.0002	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—FOXO4—skin cancer	2.06e-05	0.0002	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SMO—skin cancer	2.02e-05	0.000196	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTCH1—skin cancer	2.02e-05	0.000196	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.99e-05	0.000193	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTCH1—skin cancer	1.99e-05	0.000193	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SMO—skin cancer	1.99e-05	0.000193	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CSPG4—skin cancer	1.98e-05	0.000192	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CSPG4—skin cancer	1.97e-05	0.000191	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTGER4—skin cancer	1.97e-05	0.000191	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTGER4—skin cancer	1.94e-05	0.000188	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ENO2—skin cancer	1.9e-05	0.000184	CbGpPWpGaD
Carvedilol—XDH—Metabolism—PTGS2—skin cancer	1.89e-05	0.000183	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—FOXO4—skin cancer	1.88e-05	0.000182	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SHH—skin cancer	1.86e-05	0.000181	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—FOXO4—skin cancer	1.86e-05	0.00018	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—skin cancer	1.86e-05	0.00018	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RASA1—skin cancer	1.85e-05	0.000179	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—FOXO4—skin cancer	1.84e-05	0.000178	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—NRAS—skin cancer	1.82e-05	0.000177	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.79e-05	0.000174	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ENO2—skin cancer	1.79e-05	0.000174	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—NRAS—skin cancer	1.78e-05	0.000172	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—HRAS—skin cancer	1.78e-05	0.000172	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTCH1—skin cancer	1.77e-05	0.000171	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SMO—skin cancer	1.77e-05	0.000171	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—FOXO4—skin cancer	1.74e-05	0.000168	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SHH—skin cancer	1.73e-05	0.000168	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RASA1—skin cancer	1.72e-05	0.000167	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTGER4—skin cancer	1.72e-05	0.000167	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—FOXO4—skin cancer	1.71e-05	0.000166	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—NRAS—skin cancer	1.7e-05	0.000165	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—IL6—skin cancer	1.7e-05	0.000165	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CSPG4—skin cancer	1.68e-05	0.000163	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—BRAF—skin cancer	1.67e-05	0.000162	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—BRAF—skin cancer	1.67e-05	0.000162	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTCH1—skin cancer	1.64e-05	0.000159	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SMO—skin cancer	1.64e-05	0.000159	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PLIN2—skin cancer	1.61e-05	0.000156	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTGER4—skin cancer	1.6e-05	0.000155	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.6e-05	0.000155	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—KRAS—skin cancer	1.57e-05	0.000152	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—KRAS—skin cancer	1.53e-05	0.000148	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—FOXO4—skin cancer	1.52e-05	0.000147	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ERCC2—skin cancer	1.48e-05	0.000143	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ERCC2—skin cancer	1.48e-05	0.000143	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—KRAS—skin cancer	1.47e-05	0.000142	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ENO2—skin cancer	1.43e-05	0.000139	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FOXO4—skin cancer	1.41e-05	0.000137	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.4e-05	0.000136	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—skin cancer	1.39e-05	0.000135	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NRAS—skin cancer	1.38e-05	0.000134	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TERT—skin cancer	1.38e-05	0.000133	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ENO2—skin cancer	1.35e-05	0.000131	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ENO2—skin cancer	1.34e-05	0.00013	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—HRAS—skin cancer	1.33e-05	0.000129	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—skin cancer	1.3e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—HRAS—skin cancer	1.3e-05	0.000126	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CSPG4—skin cancer	1.3e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TERT—skin cancer	1.25e-05	0.000122	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—HRAS—skin cancer	1.25e-05	0.000121	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—IL6—skin cancer	1.25e-05	0.000121	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TERT—skin cancer	1.24e-05	0.00012	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TERT—skin cancer	1.23e-05	0.000119	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ERCC2—skin cancer	1.2e-05	0.000117	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—KRAS—skin cancer	1.19e-05	0.000115	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TERT—skin cancer	1.16e-05	0.000112	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—NRAS—skin cancer	1.16e-05	0.000112	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ENO2—skin cancer	1.14e-05	0.000111	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TERT—skin cancer	1.14e-05	0.000111	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ERCC2—skin cancer	1.1e-05	0.000107	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—BRAF—skin cancer	1.09e-05	0.000106	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—skin cancer	1.06e-05	0.000103	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—NRAS—skin cancer	1.06e-05	0.000102	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NRAS—skin cancer	1.05e-05	0.000102	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NRAS—skin cancer	1.05e-05	0.000102	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.05e-05	0.000101	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.05e-05	0.000101	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ERCC2—skin cancer	1.04e-05	0.000101	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—NRAS—skin cancer	1.03e-05	0.0001	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TERT—skin cancer	1.01e-05	9.83e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—HRAS—skin cancer	1.01e-05	9.81e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—KRAS—skin cancer	9.97e-06	9.67e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—BRAF—skin cancer	9.93e-06	9.62e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—BRAF—skin cancer	9.83e-06	9.54e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—NRAS—skin cancer	9.77e-06	9.48e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—BRAF—skin cancer	9.71e-06	9.41e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—NRAS—skin cancer	9.62e-06	9.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TERT—skin cancer	9.42e-06	9.14e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—BRAF—skin cancer	9.19e-06	8.91e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—KRAS—skin cancer	9.09e-06	8.81e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KRAS—skin cancer	9.05e-06	8.77e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—BRAF—skin cancer	9.04e-06	8.77e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KRAS—skin cancer	9.03e-06	8.75e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—KRAS—skin cancer	9.01e-06	8.73e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.93e-06	8.66e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—KRAS—skin cancer	8.89e-06	8.62e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—skin cancer	8.87e-06	8.6e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—skin cancer	8.86e-06	8.59e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ENO2—skin cancer	8.82e-06	8.55e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—NRAS—skin cancer	8.54e-06	8.28e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HRAS—skin cancer	8.48e-06	8.22e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—KRAS—skin cancer	8.41e-06	8.16e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ERCC2—skin cancer	8.31e-06	8.06e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—KRAS—skin cancer	8.28e-06	8.03e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL6—skin cancer	8.11e-06	7.87e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—skin cancer	8.04e-06	7.79e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—BRAF—skin cancer	8.03e-06	7.79e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—skin cancer	8.02e-06	7.78e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—NRAS—skin cancer	7.94e-06	7.7e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ERCC2—skin cancer	7.83e-06	7.59e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ERCC2—skin cancer	7.77e-06	7.53e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HRAS—skin cancer	7.73e-06	7.49e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—skin cancer	7.69e-06	7.45e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—skin cancer	7.67e-06	7.44e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—skin cancer	7.65e-06	7.42e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—skin cancer	7.56e-06	7.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—BRAF—skin cancer	7.46e-06	7.23e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL6—skin cancer	7.39e-06	7.17e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL6—skin cancer	7.36e-06	7.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—skin cancer	7.35e-06	7.13e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6—skin cancer	7.34e-06	7.12e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6—skin cancer	7.33e-06	7.1e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6—skin cancer	7.23e-06	7.01e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—skin cancer	7.21e-06	6.99e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—skin cancer	7.15e-06	6.93e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—skin cancer	7.04e-06	6.82e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—skin cancer	6.85e-06	6.64e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—skin cancer	6.84e-06	6.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—skin cancer	6.83e-06	6.62e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—skin cancer	6.74e-06	6.53e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ERCC2—skin cancer	6.64e-06	6.43e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—skin cancer	6.62e-06	6.42e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—skin cancer	6.25e-06	6.06e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—skin cancer	6.24e-06	6.05e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—skin cancer	6.24e-06	6.05e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—skin cancer	6.18e-06	5.99e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—skin cancer	6.1e-06	5.92e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—skin cancer	5.98e-06	5.8e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—skin cancer	5.89e-06	5.71e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—skin cancer	5.81e-06	5.63e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—skin cancer	5.77e-06	5.6e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—skin cancer	5.68e-06	5.51e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—skin cancer	5.56e-06	5.39e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—skin cancer	5.37e-06	5.21e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—skin cancer	5.32e-06	5.16e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—skin cancer	5.25e-06	5.09e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—skin cancer	5.24e-06	5.08e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ERCC2—skin cancer	5.12e-06	4.97e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—skin cancer	5.05e-06	4.89e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—skin cancer	5.01e-06	4.86e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—skin cancer	4.98e-06	4.83e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—skin cancer	4.97e-06	4.82e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—skin cancer	4.89e-06	4.74e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—skin cancer	4.79e-06	4.65e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—skin cancer	4.77e-06	4.63e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—skin cancer	4.73e-06	4.58e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—skin cancer	4.7e-06	4.55e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—skin cancer	4.69e-06	4.55e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—skin cancer	4.67e-06	4.53e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—skin cancer	4.66e-06	4.51e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—skin cancer	4.56e-06	4.42e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—skin cancer	4.52e-06	4.38e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—skin cancer	4.46e-06	4.33e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—skin cancer	4.42e-06	4.28e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—skin cancer	4.37e-06	4.23e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—skin cancer	4.35e-06	4.21e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—skin cancer	4.34e-06	4.21e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—skin cancer	4.33e-06	4.2e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—skin cancer	4.27e-06	4.14e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—skin cancer	4.22e-06	4.1e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—skin cancer	4.16e-06	4.03e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—skin cancer	4.04e-06	3.92e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—skin cancer	4.04e-06	3.91e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—skin cancer	3.98e-06	3.86e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—skin cancer	3.98e-06	3.86e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—skin cancer	3.86e-06	3.74e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—skin cancer	3.69e-06	3.58e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—skin cancer	3.59e-06	3.48e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—skin cancer	3.53e-06	3.43e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—skin cancer	3.43e-06	3.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—skin cancer	3.28e-06	3.18e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—skin cancer	3.07e-06	2.98e-05	CbGpPWpGaD
